Kolexia
Thomas Fabienne Pharmacien
Thomas Fabienne
Pharmacien
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
93 Activités
17 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Déficit en dihydropyrimidine déshydrogénase Tumeurs du sein Tumeurs colorectales Tumeurs embryonnaires et germinales Carcinome épidermoïde Carcinomes Tumeurs de la tête et du cou Effets secondaires indésirables des médicaments Récidive tumorale locale

Collaborateurs

Voir plus
Chatelut Etienne
Chatelut Etienne
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Boyer Jean-Christophe
Boyer Jean-Christophe
Hôpital Carémeau, Nîmes, France
Etienne-Grimaldi Marie-Christine
Etienne-Grimaldi Marie-Christine
Centre Antoine Lacassagne, Nice, France
Ciccolini Joseph
Ciccolini Joseph
Hôpital La Timone, Marseille, France

Industries

Voir plus
Merck-Serono
1 collaboration(s)
Dernière en 2022
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
British journal of cancer   25 janvier 2024
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
British journal of cancer   15 janvier 2024
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Clinical chemistry and laboratory medicine   11 janvier 2024
Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.
International journal of molecular sciences   20 septembre 2023
Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.
Cancer research   29 juillet 2023
Discrepancies between DPD phenotype and genotype: What are the explanatory factors?
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France   07 juin 2023
Model-informed precision dosing of high-dose IV busulfan in Thai pediatric patients
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France   07 juin 2023
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
ESMO open   31 mai 2023
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
British journal of clinical pharmacology   30 mars 2023
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
ESMO open   28 mars 2023